Clinical bottom line
Novel radiopharmaceutical therapies targeting prostate-specific membrane antigen (PSMA) represent a promising treatment avenue for metastatic castration-resistant prostate cancer (mCRPC), particularly in patients who have progressed after standard therapies. Early-phase clinical data suggest that agents such as (177)Lu-PSMA radioligand therapy ((177)Lu-PSMA-RLT), alpha-emitting compounds like (225)Ac-PSMA, and emerging radionuclides including (211)At-labeled ligands offer potential efficacy with manageable safety profiles. However, these therapies remain investigational with ongoing efforts to optimize dosing, minimize toxicity, and define patient selection criteria. Clinicians should consider these options within clinical trial settings or specialized centers experienced in radiopharmaceutical administration.
What the evidence shows
The joint EANM/SNMMI procedural guideline (Kratochwil et al., 2023) provides a comprehensive framework for the use of (177)Lu-PSMA-RLT, which has demonstrated encouraging antitumor activity in mCRPC patients refractory to chemotherapy and androgen receptor-targeted agents. This beta-emitting radioligand delivers targeted radiation to PSMA-expressing tumor cells, achieving objective responses and prolonging progression-free survival in several cohorts.
Recent preliminary results from a phase 1 study of (225)Ac-PSMA-CY313, an alpha-emitting radioligand, indicate promising safety and efficacy signals in heavily pretreated mCRPC patients (Zhang et al., 2026). Alpha emitters offer the advantage of higher linear energy transfer and shorter tissue penetration, potentially increasing tumor cell kill while sparing surrounding normal tissue. However, dose-limiting toxicities such as xerostomia remain concerns.
Zhao et al. (2026) reported on a phase 1 dose-escalation trial of [(177)Lu]Lu-P17-087, a novel rapid-clearance radioligand, showing favorable dosimetry and preliminary efficacy with an acceptable safety profile. This agent’s pharmacokinetic properties may reduce off-target radiation exposure, potentially improving tolerability.
Preclinical work by Yaginuma et al. (2025) evaluated a novel (211)At-labeled PSMA ligand with enhanced stability and antitumor efficacy in prostate cancer xenograft models. This alpha-emitter conjugate demonstrated potent tumor control and acceptable toxicity in vivo, supporting further clinical development.
Collectively, these studies underscore the evolving landscape of PSMA-targeted radiopharmaceuticals, with multiple radionuclides and ligand designs under investigation to improve therapeutic index and patient outcomes.
Caveats and uncertainty
Most clinical evidence remains early-phase, with limited sample sizes and short follow-up durations. Long-term safety data, particularly regarding renal toxicity, hematologic effects, and salivary gland damage, are incomplete. Optimal sequencing relative to other systemic therapies and the role in chemotherapy-naïve versus heavily pretreated populations require clarification.
Heterogeneity in PSMA expression and tumor burden may influence response rates, necessitating validated biomarkers for patient selection. Additionally, access to radiopharmaceutical therapies is currently limited to specialized centers with nuclear medicine expertise, which may restrict widespread adoption.
The comparative effectiveness of different radionuclides (beta vs alpha emitters) and ligand modifications remains to be established through randomized controlled trials. Potential cumulative radiation exposure and quality-of-life impacts also warrant further study.
How this may change practice
As evidence matures, PSMA-targeted radiopharmaceuticals could become integral components of mCRPC management, especially for patients with limited options after androgen receptor pathway inhibitors and chemotherapy. Incorporation into multidisciplinary care pathways will require collaboration between urologists, medical oncologists, and nuclear medicine specialists.
Clinicians should remain apprised of ongoing clinical trials and evolving guidelines, considering referral for eligible patients. Radiopharmaceutical therapy may offer a targeted approach with distinct toxicity profiles compared to conventional systemic treatments, potentially improving disease control and patient quality of life.
Future practice may also involve personalized dosimetry and combination strategies with immunotherapy or novel agents to enhance efficacy. Ultimately, robust phase 3 data and real-world experience will guide integration into standard care algorithms.